Study details
Enrolling now
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Brigham and Women's Hospital
NCT IDNCT06099093ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
30
Study length
about 1.7 years
Ages
18+
Sex
Male only
Locations
2 sites in MA
What this study is about
Researchers are testing if a new imaging test, called 18F-DCFPyL-PSMA PET, can show the extent of prostate cancer when compared to another type of diagnostic scan. The trial will last for about two years and involve men with advanced prostate cancer who are also receiving treatment with 117Lu-Vipivotide Tetraxetan.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 18F-DCFPyl
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
piflufolastat (18F)
Body systems
Oncology